Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC)
An open-label, non randomized clinical trial of Tarceva as single agent in progressed non-small cell lung cancer patients.
Non-small Cell Lung Cancer
Progression Free Survival, Defined as the time period from the entry to the study until assessed disease progression or death, 24 months
Safety, Adverse events and serious adverse events, Baseline, 4-6 months, 12 months, 24 months
Response Rate, 4-6 months, 12 months, 24 months
An observational non randomized clinical trial of Tarceva as single agent in progressed non-small cell lung cancer patients after chemotherapy.